Related Experiment Video
Updated: Aug 6, 2026
09:57
Electromagnetic Source Imaging in Presurgical Evaluation of Children with Drug-Resistant Epilepsy
Published on: September 20, 2024
Ordinary Differential Equation-Based Individualized Pharmacokinetic Simulation for Dose Optimization in an Infant
Archana Mishra1, Krishna M Gulla2, Rituparna Maiti1
1Department of Pharmacology, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India.
Neurology India
|July 21, 2026
Summary
Individualized pharmacokinetic simulations can optimize antiseizure drug (ASD) dosing in children with refractory epilepsy and global developmental delay (GDD). This approach ensures therapeutic drug levels, leading to seizure control and improved patient outcomes.
Area of Science:
- Pediatric Neurology
- Pharmacokinetics
- Epilepsy Management
Background:
- Refractory epilepsy affects 10-20% of children with global developmental delay (GDD).
- Antiseizure drugs (ASDs) have narrow therapeutic indices, necessitating careful monitoring.
- Optimizing ASD therapy is critical for managing uncontrolled seizures in this population.
Purpose of the Study:
- To illustrate the utility of pharmacokinetic simulations in optimizing ASD dosing for an infant with GDD and refractory epilepsy.
- To demonstrate the importance of individualized dosing strategies over empirical adjustments.
Main Methods:
- A case study of an infant with GDD, TBC1D24 mutation, and refractory seizures.
- Numerical solution of pharmacokinetic ordinary differential equations to simulate drug behavior.
- Dose adjustments for valproate and carbamazepine based on simulation results.
Main Results:
- Initial ASD serum levels (valproic acid, carbamazepine, phenytoin) were subtherapeutic.
- Adjusted doses of valproate (240 mg every 4 h) and carbamazepine (100 mg thrice daily) achieved therapeutic concentrations.
- The patient achieved seizure freedom after dose optimization.
Conclusions:
- Individualized pharmacokinetic simulation is a valuable tool for optimizing ASD doses in pediatric refractory epilepsy.
- This approach can lead to effective seizure control and improved therapeutic outcomes.
- Tailored dosing strategies are superior to empirical adjustments for managing complex epilepsy cases.
Related Concept Videos
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
01:29Drug Dosing: Infants and Children
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
01:24Dosage Regimen: Individualization
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...